Literature DB >> 25483538

Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012.

Silvio Tafuri1, Francesca Fortunato, Maria Giovanna Cappelli, Vanessa Cozza, Angela Bechini, Paolo Bonanni, Domenico Martinelli, Rosa Prato.   

Abstract

In Italy, between 2003 and 2010, 8/21 Regions recommended varicella routine vaccination (URV). The National Immunization Plan (PNPV) 2012-2014 scheduled the introduction of URV nationwide in 2015, following the results achieved by the eight Regions.   Puglia adopted varicella URV in 2006. This study describes epidemiology and costs of varicella in Puglia between 2003 and 2012. One-dose Vaccine Effectiveness (VE) against varicella of any severity and severe hospitalized cases in children was also evaluated. Vaccination coverage (VC) was estimated from the regional immunization registry. Incidence and hospitalization rates were calculated from computerised surveillance system for communicable diseases and hospital discharge registry (ICD9-CM codes: 052.x), respectively. URV impact was assessed by Incidence Rate Ratios (IIRs) and Hospitalization Risk Ratios (HRRs). Hospitalization costs were also evaluated. VE was estimated using the screening method, where PPV was VC in children aged <72 months and PCV was the proportion of cases vaccinated among notified or hospitalized cases, respectively. One-dose VC in children aged ≤ 24 months increased from 49% in the birth cohort 2006 to 91.1% in the cohort 2010; 2-dose VC was 64.8% and 28.8% in the 2005 and 1997 cohort, respectively. Comparing pre and post-vaccination era, incidence declined from 122.5 ×100 000 in 2003-2005 to 13.7 in 2009-2012 (IRR = 0.11, 95% CI = 0.10-0.12), hospitalization rate from 3.9 ×100 000 to 1.1 (HRR = 0.29, 95% CI = 0.21-0.4), hospitalization costs from 319 000 Euros/year to 106 000. One-dose VE against varicella of any severity and severe hospitalized disease was 98.8% and 99%, respectively. Our findings strongly support varicella URV introduction into the Italian Essential Health Interventions, as scheduled by 2015.

Entities:  

Keywords:  Varicella; breakthrough; screening method; universal routine vaccination; vaccine effectiveness; vaccine failure

Mesh:

Substances:

Year:  2014        PMID: 25483538      PMCID: PMC4514359          DOI: 10.4161/hv.36153

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

1.  The effectiveness of the varicella vaccine in clinical practice.

Authors:  M Vázquez; P S LaRussa; A A Gershon; S P Steinberg; K Freudigman; E D Shapiro
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  Assessment of varicella vaccine effectiveness in Germany: a time-series approach.

Authors:  M Höhle; A Siedler; H-M Bader; M Ludwig; U Heininger; R Von Kries
Journal:  Epidemiol Infect       Date:  2010-12-15       Impact factor: 2.451

Review 3.  Economic evaluation of Varicella vaccination: results of a systematic review.

Authors:  Brigid Unim; Rosella Saulle; Sara Boccalini; Cristina Taddei; Vega Ceccherini; Antonio Boccia; Paolo Bonanni; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

4.  Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012.

Authors:  M García Cenoz; J Castilla; J Chamorro; I Martínez-Baz; V Martínez-Artola; F Irisarri; M Arriazu; C Ezpeleta; A Barricarte
Journal:  Euro Surveill       Date:  2013-08-08

5.  Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in a region which adopted UMV.

Authors:  Silvio Tafuri; Domenico Martinelli; Rosa Prato; Cinzia Germinario
Journal:  Hum Vaccin Immunother       Date:  2012-10-29       Impact factor: 3.452

6.  Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain.

Authors:  Manuel García Cenoz; Víctor Martínez-Artola; Marcela Guevara; Carmen Ezpeleta; Aurelio Barricarte; Jesús Castilla
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

7.  Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.

Authors:  Andrea Streng; Johannes G Liese
Journal:  Vaccine       Date:  2014-01-09       Impact factor: 3.641

8.  Postlicensure study of varicella vaccine effectiveness in a day-care setting.

Authors:  D A Clements; S P Moreira; P M Coplan; C L Bland; E B Walter
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

9.  Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.

Authors:  Domenico Martinelli; Biagio Pedalino; Maria Giovanna Cappelli; Giovanni Caputi; Anna Sallustio; Francesca Fortunato; Silvio Tafuri; Vanessa Cozza; Cinzia Germinario; Maria Chironna; Rosa Prato
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

10.  Impact of vaccination on the epidemiology of varicella: 1995-2009.

Authors:  Roger Baxter; Trung N Tran; Paula Ray; Edwin Lewis; Bruce Fireman; Steve Black; Henry R Shinefield; Paul M Coplan; Patricia Saddier
Journal:  Pediatrics       Date:  2014-06-09       Impact factor: 7.124

View more
  7 in total

Review 1.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

2.  Effectiveness of one-dose versus two-dose varicella vaccine in children in Qingdao, China: a matched case-control study.

Authors:  Ping Hu; Feng Yang; Xiaofan Li; Yang Wang; Tingting Xiao; Han Li; Wencheng Wang; Jing Guan; Shanpeng Li
Journal:  Hum Vaccin Immunother       Date:  2021-10-08       Impact factor: 4.526

3.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

4.  How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project.

Authors:  R Gasparini; F S Mennini; D Panatto; P Bonanni; A Bechini; W Ricciardi; C DE Waure; A Marcellusi; A Cicchetti; M Ruggeri; S Boccalini
Journal:  J Prev Med Hyg       Date:  2015

Review 5.  Dissecting the indirect effects caused by vaccines into the basic elements.

Authors:  Carla D Scarbrough Lefebvre; Augustin Terlinden; Baudouin Standaert
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

Review 6.  The impact of varicella vaccination on varicella-related hospitalization rates: global data review.

Authors:  Maki Hirose; Alfredo Elias Gilio; Angela Esposito Ferronato; Selma Lopes Betta Ragazzi
Journal:  Rev Paul Pediatr       Date:  2016-02-17

7.  Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.

Authors:  Katsiaryna Holl; Christophe Sauboin; Emanuele Amodio; Paolo Bonanni; Giovanni Gabutti
Journal:  BMC Public Health       Date:  2016-10-21       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.